Viatris (VTRS) Change in Taxes (2020 - 2026)
Viatris' (VTRS) quarterly Change in Taxes came in at -$463.4 million in Q1 2026, down 284.25% year-on-year from $251.5 million in Q1 2025, and down 469.24% quarter-over-quarter from $125.5 million in Q4 2025.
Viatris (VTRS) Change in Taxes (2020 - 2026) Analysis & Trends
Viatris' Change in Taxes history runs 7 years deep, the most recent figure standing at -$463.4 million for Q1 2026.
- On a quarterly basis, Change in Taxes fell 284.25% year-over-year to -$463.4 million in Q1 2026; TTM through Mar 2026 was -$455.7 million, a 551.19% decrease from a year earlier, with the FY2025 full-year figure at -$112.9 million, down 151.48% from the prior year.
- Change in Taxes fell to -$463.4 million in Q1 2026 per VTRS's latest filing, from $125.5 million in the prior quarter.
- Across five years, Change in Taxes topped out at $268.2 million in Q3 2024 and bottomed at -$463.4 million in Q1 2026.
- The 5-year median for Change in Taxes is -$4.2 million (2022), against an average of -$24.0 million.
- Across the five-year window, Change in Taxes surged 3676.0% in 2024 and sank 5143.48% in 2025, its largest moves.
- Year by year, Change in Taxes stood at -$4.2 million in 2022, then slumped by 1021.43% to -$47.1 million in 2023, then sank by 43.52% to -$67.6 million in 2024, then jumped by 285.65% to $125.5 million in 2025, then plunged by 469.24% to -$463.4 million in 2026.
- Per Business Quant, the three latest VTRS Change in Taxes figures stand at -$463.4 million (Q1 2026), $125.5 million (Q4 2025), and $128.2 million (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Taxes (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | - |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | 73.00 Mn |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | -411.14 Mn |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | - |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | -463.40 Mn |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | 119.80 Mn |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | - |
| 10 | Vireo Growth | 10.57 Bn | 10.41 Bn | 59.30 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -463.40 Mn |
| Mar 31, 2026 | -463.40 Mn |
| Dec 31, 2025 | 125.50 Mn |
| Dec 31, 2025 | 125.50 Mn |
| Sep 30, 2025 | 128.20 Mn |
| Sep 30, 2025 | 128.20 Mn |
| Jun 30, 2025 | -246.00 Mn |
| Jun 30, 2025 | -246.00 Mn |
| Mar 31, 2025 | -120.60 Mn |
| Mar 31, 2025 | -120.60 Mn |
| Dec 31, 2024 | -67.60 Mn |
| Dec 31, 2024 | -67.60 Mn |
| Sep 30, 2024 | 268.20 Mn |
| Sep 30, 2024 | 268.20 Mn |
| Jun 30, 2024 | 21.00 Mn |
| Jun 30, 2024 | 21.00 Mn |
| Mar 31, 2024 | -2.30 Mn |
| Mar 31, 2024 | -2.30 Mn |
| Dec 31, 2023 | -47.10 Mn |
| Dec 31, 2023 | -47.10 Mn |